FDA mulls extending Arexvy approval to people ages 50 to 59

The FDA expects to make a decision by early June.

Related Keywords

Zhongsheng ,Anhui ,China ,Chinese ,Lynda Coughlan ,Bowonpat Sakaew ,Kathleen Neuzil ,University Of Maryland School Medicine Center ,Global Health ,Vaccine Development ,Lancet Infectious ,Zhongsheng Pharmaceutical ,Maryland School ,Medicine Center ,